3719 Results

People

  1. Hudis
    Hudis
  2. Lee
    Lee
  3. Giralt
    Giralt
  4. Motzer
    Motzer
  5. Barakat
    Barakat
  6. Scher
    Scher
  7. Ladanyi
    Ladanyi
  8. Levine
    Levine
  9. Chi
    Chi
  10. DeMatteo
    DeMatteo

Groups

  1. Department of Medicine (1284)
  2. Surgery (899)
  3. GSK Faculty (811)
  4. Solid Tumor Oncology Division (708)
  5. Survivorship Research (632)
  6. Sloan Kettering Institute Faculty (579)
  7. Center for Hematologic Malignancies (503)
  8. Department of Pathology and Laboratory Medicine (470)
  9. Population Sciences Research Program (431)
  10. Epidemiology and Biostatistics (426)
  1. "2012"
Formats
  1. Journal Article (2365)
  2. Meeting Abstract (1182)
  3. Book Section (137)
  4. Conference Paper (23)
  5. Book Whole (10)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (1284)
  2. Surgery (899)
  3. GSK Faculty (811)
  4. Solid Tumor Oncology Division (708)
  5. Survivorship Research (632)
  6. Sloan Kettering Institute Faculty (579)

More Groups

People
  1. Clifford Hudis (64)
  2. Nancy Lee (64)
  3. Sergio Giralt (59)
  4. Robert Motzer (57)
  5. Richard Barakat (54)
  6. Howard Scher (53)

More People

Years
  1. 2012 (3719)
Publications
  1. Journal of Clinical Oncology (315)
  2. Blood (152)
  3. International Journal of Radiation Oncology, Biology, Physics (125)
  4. Cancer Research (110)
  5. Modern Pathology (80)
  6. Gynecologic Oncology (76)

More Publications

Publishers
  1. Elsevier Inc. (519)
  2. American Society of Clinical Oncology (337)
  3. Springer (239)
  4. Nature Publishing Group (202)
  5. Wiley Blackwell (193)
  6. American Association for Cancer Research (192)

More Publishers

Results (3719)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors
    Meeting Abstract

    Kurzrock, R.; Blay, J. Y.; Nguyen, B. B.; Wagner, A. J.; Maki, R. G.; Schwartz, G. K.; Patnaik, A.; Gore, L.; Wu, L.; Vassilev, L. T.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC)
    Meeting Abstract

    Klepin, H. D.; Pitcher, B.; Ballman, K. V.; Kimmick, G. G.; Kornblith, A. B.; Cohen, H. J.; Hurria, A.; Winer, E. P.; Hudis, C.; Muss, H. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS)
    Meeting Abstract

    Kopp, L. M.; Bernstein, M. L.; Schwartz, C. L.; Ebb, D.; Krailo, M. D.; Grier, H. E.; Meyers, P. A.; Wexler, L. H.; Marina, N.; Womer, R.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Janne, P. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
    Meeting Abstract

    Kitano, S.; Postow, M. A.; Cortez, C.; Rasalan, T.; Gallardo, H. F.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Lesokhin, A. M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Wozniak, A. J.; Kindler, H. L.; Feld, R.; Koczywas, M.; Morero, J. L.; Rodriguez, C. P.; Ross, H. J.; Bauman, J. E.; Orlov, S. V.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)
    Meeting Abstract

    Kirkwood, J. M.; Long, G. V.; Trefzer, U.; Davies, M. A.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Kefford, R.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    Meeting Abstract

    Kelly, W. K.; Halabi, S.; Carducci, M. A.; George, D. J.; Mahoney, J. F.; Stadler, W. M.; Morris, M. J.; Kantoff, P. W.; Monk, J. P.; Small, E. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Usefulness of medical oncologists' estimates of survival time in people with advanced cancer
    Meeting Abstract

    Kiely, B. E.; Martin, A. J.; Tattersall, M. H. N.; Nowak, A. K.; Goldstein, D.; Wilcken, N.; Wyld, D.; Beale, P. J.; Jefford, M.; Glasgow, A. L.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Ahn, M. J.; Shi, Y.; De Pas, T. M.; Yang, P. C.; Riely, G. J.; Crino, L.; Evans, T. L.; Liu, X.; Han, J. Y.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save